Literature DB >> 1669840

Aspirin use and reduced risk of fatal colon cancer.

M J Thun1, M M Namboodiri, C W Heath.   

Abstract

BACKGROUND AND METHODS: Experiments in animals and two epidemiologic studies in humans suggest that aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) may be protective against colon cancer. We tested this hypothesis in a prospective mortality study of 662,424 adults who provided information in 1982 on the frequency and duration of their aspirin use. Death rates from colon cancer were measured through 1988. The possible influence of other risk factors for colon cancer was examined in multivariate analyses for 598 case patients and 3058 matched control subjects drawn from the cohort.
RESULTS: Death rates from colon cancer decreased with more frequent aspirin use in both men and women. The relative risk among persons who used aspirin 16 or more times per month for at least one year was 0.60 in men (95 percent confidence interval, 0.40 to 0.89) and 0.58 in women (95 percent confidence interval, 0.37 to 0.90). The risk estimates were unaffected when we excluded persons who reported at entry into the study that they had cancer, heart disease, stroke, or another condition that might influence both their aspirin use and their mortality. Adjustment for dietary factors, obesity, physical activity, and family history did not alter the findings significantly. No association was found between the use of acetaminophen and the risk of colon cancer.
CONCLUSIONS: Regular aspirin use at low doses may reduce the risk of fatal colon cancer. Whether this is due to a direct effect of aspirin, perhaps mediated by the inhibition of prostaglandin synthesis, or to other factors indirectly associated with aspirin use is unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1669840     DOI: 10.1056/NEJM199112053252301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  298 in total

1.  Screening for familial adenomatous polyposis.

Authors:  W Hyer; J M Fell
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 2.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

3.  Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.

Authors:  C S Williams; A P Goldman; H Sheng; J D Morrow; R N DuBois
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

4.  Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.

Authors:  X M Xu; L Sansores-Garcia; X M Chen; N Matijevic-Aleksic; M Du; K K Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.

Authors:  Noriyuki Omura; Margaret Griffith; Audrey Vincent; Ang Li; Seung-Mo Hong; Kimberly Walter; Michael Borges; Michael Goggins
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

6.  Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Dipak K Majumdar
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

7.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

8.  Human ortholog of a plant salicylic acid receptor found in SK-N-SH cell line.

Authors:  Hanna Skubatz; William N Howald
Journal:  Protein J       Date:  2013-12       Impact factor: 2.371

9.  NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect?

Authors:  Elizabeth B Lamont; Lauren E Dias; Diane S Lauderdale
Journal:  J Gen Intern Med       Date:  2007-06-19       Impact factor: 5.128

10.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.